Home › Companies › Anika Therapeutics, Inc. › 2025-2026

Anika Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Anika Therapeutics, Inc.’s Form 8-K, filed 2026-06-23 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 8Reported items
  • 168Asset managers
  • 1,200Fund votes
  • 2026-06-18Meeting date

Proxy season: 2024-2025 2025-2026

Explore Anika Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Anika Therapeutics, Inc.

These tallies are Anika Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Anika Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-18
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Gary P. Fischetti 9,248,053117,96727,781 --1,801,866 Majority: yes
Elect Director: John B. Henneman, III 8,829,035536,98827,778 --1,801,866 Majority: yes
Elect Director: Stephen D. Griffin 9,309,70756,27627,818 --1,801,866 Majority: yes

Source: Anika Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-23 — read the filing on EDGAR.

How asset managers voted at the Anika Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 168 asset managers that disclosed a Anika Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Anika Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

90% fund support · no official result

FOR 90%10%

The 164 asset managers below cast 90% of the shares they voted on this item FOR (8,133,616 for, 917,861 against).

FOR: 8,133,616 (89.9%)AGAINST: 917,861 (10.1%)
Largest asset managers voting on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,373,8470 00For
Caligan Partners LP1,293,0590 00For
Vanguard764,4112 00For
Renaissance487,8660 00For
ACADIAN ASSET MANAGEMENT LLC437,2850 00For
BOOTHBAY FUND MANAGEMENT, LLC388,4320 00For
GEODE CAPITAL MANAGEMENT, LLC331,1370 00For
Fidelity324,6720 00For
State Street318,8200 00For
American Century0270,874 00Against
DE Shaw233,7880 00For
Charles Schwab227,6190 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC0209,757 00Against
Dimensional0180,297 00Against
AQR177,9050 00For
JACOBS LEVY EQUITY MANAGEMENT, INC168,3740 00For
Two Sigma163,2040 00For
Nuveen155,7960 00For
TIAA155,2280 00For
Goldman Sachs154,4740 00For
Northern Trust98,7930 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/086,927 00Against
ENVESTNET ASSET MANAGEMENT INC63,2010 00For
MFS061,927 00Against
Point7252,5530 00For

Showing the 25 largest of 164 asset managers. See all 164 in the interactive database.

2. Election of three Class III Directors: Gary P. Fischetti

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 9,248,053AGAINST: 117,967

Anika Therapeutics, Inc.’s own tally for this item (“Elect Director: Gary P. Fischetti”): 9,248,053 for, 117,967 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 13,357,000 outstanding shares: 69% for, 0.9% against (70% of the company cast a for/against vote).

The 50 asset managers below cast 99.2% of the shares they voted on this item FOR (2,291,950 for, 17,981 against).

FOR 99.2%
FOR: 2,291,950 (99.2%)AGAINST: 17,981 (0.8%)
Largest asset managers voting on “Election of three Class III Directors: Gary P. Fischetti” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard669,3730 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA155,2280 00For
American Century135,4370 00For
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable18,97913,200 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs18,5830 00For
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial12,3810 00For
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust9,8450 00For
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. Election of three Class III Directors: John B. Henneman, III

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 8,829,035AGAINST: 536,988

Anika Therapeutics, Inc.’s own tally for this item (“Elect Director: John B. Henneman, III”): 8,829,035 for, 536,988 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 13,357,000 outstanding shares: 66% for, 4% against (70% of the company cast a for/against vote).

The 50 asset managers below cast 98% of the shares they voted on this item FOR (2,269,670 for, 40,261 against).

FOR 98%
FOR: 2,269,670 (98.3%)AGAINST: 40,261 (1.7%)
Largest asset managers voting on “Election of three Class III Directors: John B. Henneman, III” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard667,6881,685 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA155,2280 00For
American Century135,4370 00For
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable18,97913,200 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs18,5830 00For
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial2,9869,395 00Against
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust09,845 00Against
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. Election of three Class III Directors: Stephen D. Griffin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 9,309,707AGAINST: 56,276

Anika Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephen D. Griffin”): 9,309,707 for, 56,276 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 13,357,000 outstanding shares: 70% for, 0.5% against (70% of the company cast a for/against vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (2,309,931 for, 0 against).

FOR 100%
FOR: 2,309,931 (100.0%)
Largest asset managers voting on “Election of three Class III Directors: Stephen D. Griffin” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard669,3730 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA155,2280 00For
American Century135,4370 00For
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable32,1790 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs18,5830 00For
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial12,3810 00For
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust9,8450 00For
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (2,309,931 for, 0 against).

FOR: 2,309,931 (100.0%)
Largest asset managers voting on “RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE FISCAL Y” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard669,3730 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA155,2280 00For
American Century135,4370 00For
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable32,1790 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs18,5830 00For
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial12,3810 00For
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust9,8450 00For
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. APPROVAL OF THE AMENDMENT TO THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

86% fund support · no official result

FOR 86%AGAINST 14%

The 50 asset managers below cast 86% of the shares they voted on this item FOR (1,975,586 for, 330,696 against).

FOR: 1,975,586 (85.5%)AGAINST: 330,696 (14.3%)ABSTAIN: 3,649 (0.2%)
Largest asset managers voting on “APPROVAL OF THE AMENDMENT TO THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN.” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard668,2371,136 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA0155,228 00Against
American Century0135,437 00Against
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable32,1790 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs018,583 00Against
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial2,9869,395 00Against
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust9,8450 00For
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

7. Approval of the Amendment of the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan

COMPENSATION

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (2,309,930 for, 1 against).

FOR: 2,309,930 (100.0%)AGAINST: 1 (0.0%)
Largest asset managers voting on “Approval of the Amendment of the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard669,3721 00For
BlackRock425,3720 00For
Fidelity302,4680 00For
TIAA155,2280 00For
American Century135,4370 00For
Dimensional120,3900 00For
Charles Schwab113,2280 00For
MFS61,9270 00For
Nationwide47,5690 00For
Columbia Threadneedle35,5150 00For
Equitable32,1790 00For
GuideStone23,8880 00For
Invesco19,8620 00For
Goldman Sachs18,5830 00For
BRIDGEWAY FUNDS INC17,5000 00For
Lincoln Financial12,3810 00For
QUANTITATIVE MASTER SERIES LLC10,0370 00For
Northern Trust9,8450 00For
Thrivent9,1990 00For
MASTER INVESTMENT PORTFOLIO8,6810 00For
AIG/SunAmerica6,5350 00For
Venerable Variable Insurance Trust6,3970 00For
Global X5,3760 00For
Jackson National5,2440 00For
Bridge Builder Trust5,1910 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

8. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (88,898 for, 0 against).

FOR: 88,898 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Anika Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
GLOBEFLEX CAPITAL L P87,6000 00For
ALGERT GLOBAL LLC1,2980 00For

Largest Anika Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Anika Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 13,357,000 shares outstanding at the time of that meeting.

Top Anika Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 10.29%
2Caligan Partners LP 9.68%
3Vanguard 5.72%
4Renaissance 3.65%
5ACADIAN ASSET MANAGEMENT LLC 3.27%
6BOOTHBAY FUND MANAGEMENT, LLC 2.91%
7GEODE CAPITAL MANAGEMENT, LLC 2.48%
8Fidelity 2.43%
9State Street 2.39%
10American Century 2.03%

Reported Anika Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Anika Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 11.94% 13F
Caligan Partners LP 10.74% 13D
Vanguard Group 5.83% 13F
Morgan Stanley 5.78% 13F
Renaissance Technologies 3.76% 13F
Dimensional Fund Advisors 3.44% 13F
State Street 2.59% 13F
Two Sigma 1.77% 13F
D.E. Shaw 1.72% 13F
Trigran Investments, Inc. 1.26% 13G

Percentages above are of 13,357,000 shares outstanding, as reported by Anika Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Anika Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Anika Therapeutics, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 168 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,200 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Anika Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — the reporting funds cast 90% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Anika Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).